W
Walter H. Moos
Researcher at University of California, San Francisco
Publications - 120
Citations - 4974
Walter H. Moos is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Peptoid & Cognitive decline. The author has an hindex of 29, co-authored 119 publications receiving 4656 citations. Previous affiliations of Walter H. Moos include Parke-Davis & SRI International.
Papers
More filters
Journal ArticleDOI
Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis
TL;DR: In this article, the authors present an automated solid-phase method for the synthesis of oligo(N-substituted glycines) (NSGs) which is general for a wide variety of side-chain substituents and allows the rapid synthesis of molecules of potential therapeutic interest.
Journal ArticleDOI
Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers
TL;DR: The N‐substituted glycine peptoids represent a new class of combinatorial diversity for lead discovery with improved pharmaceutical characteristics relative to L‐amino acid containing peptides.
Journal ArticleDOI
Measuring Diversity: Experimental Design of Combinatorial Libraries for Drug Discovery
Eric J. Martin,Jeffrey M. Blaney,Michael A. Siani,David C. Spellmeyer,Alexander Wong,Walter H. Moos +5 more
TL;DR: New methods to quantify molecular diversity using descriptors that characterize lipophilicity, shape and branching, chemical functionality, and specific binding features are described and quantify the overall diversity accessible to different families of combinatorial chemistry.
Journal ArticleDOI
Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers
TL;DR: All-L peptides were readily cleaved by the appropriate enzymes, while equivalent all-D and N-substituted glycine containing oligomers were not.
Journal ArticleDOI
A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
Peter B. Madrid,Sidharth Chopra,Ian D. Manger,Lynne Gilfillan,Tiffany R. Keepers,Amy C. Shurtleff,Carol E. Green,Lalitha V. Iyer,Holli Hutcheson Dilks,Robert A. Davey,Andrey A. Kolokoltsov,Ricardo Carrion,Jean L. Patterson,Sina Bavari,Rekha G. Panchal,Travis K. Warren,Jay Wells,Walter H. Moos,RaeLyn L. Burke,Mary J. Tanga +19 more
TL;DR: The feasibility of repurposing existing drugs to face novel threats is demonstrated and this represents the first effort to apply this approach to high containment bacteria and viruses.